Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 36 (6), 493-503

Interleukin-32β Stimulates Migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 Signaling Pathway


Interleukin-32β Stimulates Migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 Signaling Pathway

Jeong Su Park et al. Cell Oncol (Dordr).


Background: IL-32 is known to play an important role in inflammatory and autoimmune disease responses. In addition to its role in these responses, IL-32 and its different isoforms have in recent years been implicated in the development of various cancers. As of yet, the role of IL-32 in breast cancer has remained largely unknown.

Results: By performing immunohistochemical assays on primary breast cancer samples, we found that the level of IL-32β expression was positively correlated with tumor size, number of lymph node metastases and tumor stage. In addition, we found that breast cancer-derived MDA-MB-231 cells exogenously expressing IL-32β exhibited increased migration and invasion capacities. These increased capacities were found to be associated with an increased expression of the epithelial mesenchymal transition (EMT) markers vimentin and Slug, the latter of which is responsible for the increase in vimentin transcription. To next investigate whether IL-32β enhances migration and invasion through a soluble factor, we determined the levels of several migration-stimulating ligands, and found that the production of VEGF was increased by IL-32β. In addition, we found that IL-32β-induced VEGF increased migration and invasion through STAT3 activation.

Conclusion: The IL-32β-VEGF-STAT3 pathway represents an additional pathway that mediates the migration and invasion of breast cancer cells under the conditions of normoxia and hypoxia.

Similar articles

See all similar articles

Cited by 22 articles

See all "Cited by" articles


    1. J Cell Biol. 2004 Oct 25;167(2):223-9 - PubMed
    1. Autoimmun Rev. 2007 Jan;6(3):131-7 - PubMed
    1. J Allergy Clin Immunol. 2012 Apr;129(4):964-73.e7 - PubMed
    1. Oncogene. 2002 Mar 27;21(13):2000-8 - PubMed
    1. Immunity. 2005 Jan;22(1):131-42 - PubMed

Publication types

MeSH terms

LinkOut - more resources